caracurine V: isolated from stembark of Strychnos chrysophylla [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Strychnos | genus | A plant genus of the family LOGANIACEAE (classified by some botanists as Strychnaceae).[MeSH] | Loganiaceae | A plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida. They have leaflike appendages at the base of the leafstalks, have terminal flower clusters. Petals have four or five overlapping lobes and the fruit is a capsule containing winged or wingless seeds.[MeSH] |
| Strychnos chrysophylla | species | [no description available] | Loganiaceae | A plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida. They have leaflike appendages at the base of the leafstalks, have terminal flower clusters. Petals have four or five overlapping lobes and the fruit is a capsule containing winged or wingless seeds.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 168927 |
| CHEBI ID | 3382 |
| MeSH ID | M0123171 |
| Synonym |
|---|
| 630-87-5 |
| caracurine v |
| chebi:3382 , |
| bdbm50025037 |
| Q27106055 |
| (1r,9r,16s,18r,19r,20s,21r,29r,36s,38r,39r,40s)-10,30-dioxa-8,15,28,35-tetrazatridecacyclo[33.5.2.215,21.01,36.02,7.08,40.09,19.013,18.016,21.020,28.022,27.029,39.033,38]tetratetraconta-2,4,6,12,22,24,26,32-octaene |
| Class | Description |
|---|---|
| alkaloid | Any of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Sus scrofa (pig) | EC50 (µMol) | 0.4360 | 0.0135 | 1.8625 | 6.3096 | AID1162774 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | EC50 (µMol) | 0.4365 | 0.0000 | 0.7378 | 10.0000 | AID262091 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.4360 | 0.0007 | 0.4236 | 1.7650 | AID1162774 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein-coupled acetylcholine receptor activity | Muscarinic acetylcholine receptor M2 | Homo sapiens (human) |
| arrestin family protein binding | Muscarinic acetylcholine receptor M2 | Homo sapiens (human) |
| G protein-coupled serotonin receptor activity | Muscarinic acetylcholine receptor M2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID262092 | Displacement of (+/-)-[3H]epibatidine from muscle type nAChR of Torpedo californica in hepes buffer | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | 6H,13H-Pyrazino[1,2-a;4,5-a']diindole analogs: probing the pharmacophore for allosteric ligands of muscarinic M2 receptors. |
| AID142674 | Concentration for half maximal inhibition of [3H]NMS dissociation from muscarinic acetylcholine receptor M2 in porcine heart ventricles | 2004 | Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14 | Probing the pharmacophore for allosteric ligands of muscarinic M2 receptors: SAR and QSAR studies in a series of bisquaternary salts of caracurine V and related ring systems. |
| AID262091 | Inhibition of [3H]NMS dissociation from muscarinic M2 receptor in Na,K,Pi buffer | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | 6H,13H-Pyrazino[1,2-a;4,5-a']diindole analogs: probing the pharmacophore for allosteric ligands of muscarinic M2 receptors. |
| AID1162774 | Displacement of [3H]NMS from pig muscarinic M2 receptor after 120 mins by liquid scintillation counting | 2014 | Journal of natural products, Sep-26, Volume: 77, Issue:9 | Semisynthetic analogues of toxiferine I and their pharmacological properties at α7 nAChRs, muscle-type nAChRs, and the allosteric binding site of muscarinic M2 receptors. |
| AID142668 | Concentration for equilibrium binding to muscarinic acetylcholine receptor M2 using [3H]NMS in porcine heart ventricles | 2004 | Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14 | Probing the pharmacophore for allosteric ligands of muscarinic M2 receptors: SAR and QSAR studies in a series of bisquaternary salts of caracurine V and related ring systems. |
| AID1162773 | Displacement of [3H]epibatidine from Torpedo californica muscle-type nAChR after 90 mins by liquid scintillation counting | 2014 | Journal of natural products, Sep-26, Volume: 77, Issue:9 | Semisynthetic analogues of toxiferine I and their pharmacological properties at α7 nAChRs, muscle-type nAChRs, and the allosteric binding site of muscarinic M2 receptors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||